Sagimet Biosciences (SGMT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Company overview and scientific focus

• Focuses on fatty acid synthase pathway, targeting MASH, acne, and oncology, with primary work in MASH.

• Lead molecule, denifenstat, is a fat inhibitor, uniquely reducing fat, inflammation, and fibrosis independently.

• Completed a phase IIb study with pronounced effects, especially in reducing fibrosis, and presented full data at the European Liver Meeting.

• Drug is well-tolerated and safe across over 700 patients in various indications.

Clinical data and competitive positioning

• Denifenstat demonstrated superior placebo-adjusted fibrosis improvement compared to other drugs at one year.

• F3 patient subgroup showed three times the treatment effect versus resmetirom and 50% greater than tirzepatide.

• Statistically significant reduction in progression to cirrhosis compared to placebo.

• Combination with GLP-1s and resmetirom in preclinical and clinical settings showed enhanced efficacy, especially in fibrosis.

• Drug is positioned as both a strong monotherapy and an ideal backbone for future combination regimens.

Biomarkers, safety, and precision medicine

• Tripalmitin identified as a unique biomarker for on-target FASN activity and early treatment response.

• Plans to leverage tripalmitin for precision medicine, aiding patient selection and payer discussions.

• Triglyceride shift from saturated to polyunsaturated fats is seen as a positive cardiometabolic effect.

• On-target adverse events include dry eye (more common in placebo) and hair thinning, which is reversible and manageable with dose reduction or supportive care.